Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site No. #001302
mi
from
Royal Oak, MI
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site No. #001302
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site #001209
mi
from
Columbia, MO
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site #001209
mi
from
Columbia, MO
Click here to add this to my saved trials
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site #054010
mi
from
Godoy Cruz,
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site #054010
mi
from
Godoy Cruz,
Click here to add this to my saved trials
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated:  12/31/1969
Merz Investgational Site #001284
mi
from
Loxahatchee Groves, FL
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status: Enrolling
Updated: 12/31/1969
Merz Investgational Site #001284
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 04
mi
from
La Jolla, CA
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 04
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 038
mi
from
Englewood, CO
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 038
mi
from
Englewood, CO
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12287
mi
from
Washington,
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12287
mi
from
Washington,
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1370
mi
from
Baltimore, MD
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1370
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1370
mi
from
Baltimore, MD
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1370
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1353
mi
from
Manhasset, NY
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1353
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10112
mi
from
Rochester, NY
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10112
mi
from
Rochester, NY
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Winston-Salem, NC
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Cincinnati, OH
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10166
mi
from
Pittsburgh, PA
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10166
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1343
mi
from
Salt Lake City, UT
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1343
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 09
mi
from
Richmond, VA
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 09
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1323
mi
from
Kirkland, WA
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1323
mi
from
Kirkland, WA
Click here to add this to my saved trials
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 78055
mi
from
Caulfield South,
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 78055
mi
from
Caulfield South,
Click here to add this to my saved trials
Brain Biomarkers of Response to Treatment for Apraxia of Speech
Brain Biomarkers of Response to Treatment for Apraxia of Speech
Status: Enrolling
Updated:  12/31/1969
VA Northern California Health Care System, Mather, CA
mi
from
Sacramento, CA
Brain Biomarkers of Response to Treatment for Apraxia of Speech
Brain Biomarkers of Response to Treatment for Apraxia of Speech
Status: Enrolling
Updated: 12/31/1969
VA Northern California Health Care System, Mather, CA
mi
from
Sacramento, CA
Click here to add this to my saved trials
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Status: Enrolling
Updated:  12/31/1969
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Status: Enrolling
Updated: 12/31/1969
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Click here to add this to my saved trials
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Status: Enrolling
Updated:  12/31/1969
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
mi
from
New York, NY
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Status: Enrolling
Updated: 12/31/1969
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
mi
from
New York, NY
Click here to add this to my saved trials
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Intravenous Exenatide in Patients With Acute Brain Injury
Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury
Status: Enrolling
Updated:  12/31/1969
University of North Carolina; UNC Medical Center
mi
from
Chapel Hill, NC
Intravenous Exenatide in Patients With Acute Brain Injury
Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury
Status: Enrolling
Updated: 12/31/1969
University of North Carolina; UNC Medical Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes
Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes
Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety of Simvastatin in LAM and TSC
The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Safety of Simvastatin in LAM and TSC
The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis School of Medicine
mi
from
Saint Louis, MO
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
University of Arizona
mi
from
Tucson, AZ
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
St. Jude Medical Center
mi
from
Fullerton, CA
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
St. Jude Medical Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Hoag Memorial Hospital
mi
from
Newport Beach, CA
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
University of California Los Angeles
mi
from
Santa Monica, CA
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
University of California Los Angeles
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Medical Center of the Rockies
mi
from
Loveland, CO
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Medical Center of the Rockies
mi
from
Loveland, CO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Associated Neurologists, P.C.
mi
from
Danbury, CT
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Associated Neurologists, P.C.
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Associated Neurologists of Southern Ct., PC
mi
from
Fairfield, CT
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Associated Neurologists of Southern Ct., PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Services; Sponsor Programs Ammon Education Center
mi
from
Newark, DE
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Services; Sponsor Programs Ammon Education Center
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Nova Clinical Research, Llc
mi
from
Bradenton, FL
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Nova Clinical Research, Llc
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Neurologic Consultants, PA
mi
from
Fort Lauderdale, FL
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Neurologic Consultants, PA
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine; Clinical Reseach Building
mi
from
Miami, FL
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine; Clinical Reseach Building
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials